Federated Hermes Inc. Grows Stake in ICU Medical, Inc. (NASDAQ:ICUI)

Federated Hermes Inc. increased its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 39.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 176,232 shares of the medical instruments supplier’s stock after purchasing an additional 50,265 shares during the period. Federated Hermes Inc. owned 0.73% of ICU Medical worth $17,577,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Private Trust Co. NA grew its holdings in shares of ICU Medical by 1,428.6% during the third quarter. Private Trust Co. NA now owns 321 shares of the medical instruments supplier’s stock worth $38,000 after buying an additional 300 shares in the last quarter. SG Americas Securities LLC purchased a new stake in ICU Medical during the 4th quarter valued at about $106,000. Knights of Columbus Asset Advisors LLC raised its holdings in ICU Medical by 16.7% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 1,848 shares of the medical instruments supplier’s stock valued at $220,000 after acquiring an additional 264 shares during the last quarter. Xponance Inc. lifted its stake in ICU Medical by 17.8% in the 3rd quarter. Xponance Inc. now owns 2,902 shares of the medical instruments supplier’s stock worth $345,000 after purchasing an additional 439 shares in the last quarter. Finally, Dark Forest Capital Management LP acquired a new position in shares of ICU Medical during the 3rd quarter worth approximately $383,000. 96.10% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, COO Christian B. Voigtlander sold 13,603 shares of the firm’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $107.19, for a total transaction of $1,458,105.57. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other ICU Medical news, Director George A. Lopez sold 1,890 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $104.22, for a total transaction of $196,975.80. Following the transaction, the director now directly owns 317,753 shares in the company, valued at $33,116,217.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Christian B. Voigtlander sold 13,603 shares of ICU Medical stock in a transaction on Monday, March 4th. The shares were sold at an average price of $107.19, for a total value of $1,458,105.57. The disclosure for this sale can be found here. Insiders have sold a total of 24,262 shares of company stock valued at $2,545,532 in the last quarter. Insiders own 6.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, KeyCorp increased their price target on ICU Medical from $134.00 to $136.00 and gave the company an “overweight” rating in a report on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $123.00.

ICU Medical Trading Up 0.6 %

Shares of ICUI opened at $96.38 on Tuesday. The company has a current ratio of 2.53, a quick ratio of 1.06 and a debt-to-equity ratio of 0.74. The firm has a 50-day moving average price of $102.15 and a 200 day moving average price of $98.19. ICU Medical, Inc. has a 12-month low of $78.28 and a 12-month high of $212.43. The firm has a market capitalization of $2.35 billion, a P/E ratio of -78.36 and a beta of 0.69.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Tuesday, February 27th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.39. The business had revenue of $587.86 million during the quarter, compared to the consensus estimate of $564.77 million. ICU Medical had a negative net margin of 1.31% and a positive return on equity of 6.35%. Sell-side analysts forecast that ICU Medical, Inc. will post 3.52 EPS for the current year.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.